<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1267">
  <stage>Registered</stage>
  <submitdate>22/08/2006</submitdate>
  <approvaldate>22/08/2006</approvaldate>
  <nctid>NCT00367952</nctid>
  <trial_identification>
    <studytitle>A Long Term, Safety Study of Apricitabine in HIV-infected Subjects</studytitle>
    <scientifictitle>An Open Label Long Term Safety Extension Study of Apricitabine in Treatment-experienced HIV-1 Infected Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AVX-201E</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - apricitabine

Experimental: ATC 800mg BID - 800mg ATC BID


Treatment: drugs: apricitabine
800mg apricitabine twice daily orally for 96 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to virological failure (DHSS definition)</outcome>
      <timepoint>week 144</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>incidence of AEs and laboratory abnormalities</outcome>
      <timepoint>Week 144</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>time to withdrawal due to AEs</outcome>
      <timepoint>Week 144</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline HIV RNA</outcome>
      <timepoint>weeks 72, 96, 120, and 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with plasma HIV RNA &lt;400 and &lt;50 copies/ml</outcome>
      <timepoint>at weeks 72, 96, 120, and 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline and change in ratio of CD4+ and CD8+ counts</outcome>
      <timepoint>at weeks 72, 96, 120, and 144</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Completed AVX-201 protocol, Plasma HIV RNA &lt;5000 copies/ml, CD4 cells &gt;50</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or breastfeeding females, withdrawal from AVX-201</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>42</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Avexa (co-ordinating sites in Australia and Argentina) - Melbourne</hospital>
    <postcode>3121 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avexa</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will examine how safe and effective apricitabine is when given long term (as
      ongoing treatment) to HIV patients who have already completed the AVX-201 trial</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00367952</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Susan W Cox, Ph D</name>
      <address>Avexa</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>